En Es

Industry News

QIAGEN Enters into Agreement to Acquire STAT-Dx

By Labmedica International staff writers
13 Feb 2018

Image: Qiagen plans to acquire diagnostics developer STAT-Dx for up to $191 million, in a deal designed to facilitate the buyer's planned launch later this year of the QIAstat-Dx platform, based on STAT-Dx’s proprietary DiagCORE technology (Photo courtesy of STAT-Dx).QIAGEN N.V. (The Netherlands) has entered into an agreement to acquire STAT-Dx (Barcelona, Spain), a privately-held company which develops next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries.

The system, which will be branded as QIAstat-Dx, enables scalable Sample to Insight processing of up to 48 molecular targets simultaneously for diagnosing syndromes, such as serious respiratory or gastrointestinal infections, as well as for use in oncology. With cost-efficient, easy-to-use assays suitable for any clinical sample type, the system can provide qualitative as well as quantitative insights into the precise cause of various syndromes in about one hour.

Based on the proprietary DiagCORE technology, the system received a first CE-IVD marking in January 2018. The system utilizes cost-efficient, single-use cartridges with built-in sample processing and all reagents on board. The cartridges are loaded with QIAGEN sample and assay technologies and a lab technician only needs to load a clinical sample into a cartridge and place it in the analyzer, requiring less than one minute of hands-on time.

The flexible modular system, which has bi-directional LIS (laboratory information system) interface capabilities, is designed to operate in a range of near-patient clinical settings, eliminating the delay of sending samples to a centralized laboratory. The cartridges are processed in a scalable, proprietary and fully integrated platform, which can be configured from one to eight modules, independently running cartridges with predefined assay protocols and managed via a touchscreen that offers simple step-by-step directions.

QIAstat-Dx is planned to be further developed with the aim of becoming the first analyzer that combines capabilities to run the highest multiplexing molecular diagnostic assays with the ability to quantitate and also process immunoassays. The first two tests, which are extensive respiratory and gastrointestinal (GI) panels, are to be launched in Europe in the second half of 2018, in the US in 2019 following regulatory clearance, and in other markets worldwide. Additional tests are under development for infectious diseases, immune response monitoring, oncology and companion diagnostics.

“QIAstat-Dx represents the next generation of innovation for multiplex syndromic testing, using powerful QIAGEN technologies and a real-time PCR technology that will allow for a much broader range of applications and drive the dissemination of molecular testing. The system is designed for significantly more cost-efficient test processing as required by the current reimbursement environment. Additional application areas for this system include companion diagnostics, quantitative analysis and immunoassay tests, offering customers a new level of flexibility and accurate diagnosis designed to support better outcomes for patients and healthcare systems,” said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. “We look forward to adding QIAstat-Dx to our portfolio of Sample to Insight solutions. This is further confirmation as to how we are leveraging our advantages in sample and assay technologies, our leadership in providing solutions for infectious disease testing and the global reach of our commercial teams.”

“We are excited about accelerating the commercialization of our technology to bring fast, cost-effective syndromic testing closer to care for patients and healthcare providers. At the closing of the transaction, we will build on the achievements of our fantastic team in developing a best-in-class system and leverage QIAGEN’s resources with extensive R&D and commercial reach around the world,” said Jordi Carrera, co-founder and Chief Executive Officer of STAT-Dx.

E-mail Print
FaceBook Twitter Google+ Linked in


Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including complete kits for pre-defined applications in sample preparation and analysis, and individual enzymes and reagents. It also offers instruments for automating the full range of laboratory procedures, from the initial sample preparation to the final test result.
More info

More articles about QIAGEN

12 Jan 2017
Qiagen Acquires Bioinformatics Firm OmicSoft
QIAGEN N.V., a provider of sample and assay technologies, has acquired OmicSoft Corporation, which focuses on biomarker data management, visualization, and analysis.
Read More

Additional news

10 Aug 2018
Global Medical Robots Market to Reach USD 16 Billion by 2023
The global medical robots market is projected to grow at a CAGR of 21.0% from an estimated USD 6.46 billion in 2018 to USD 16.74 billion by 2023, driven by technological advancements, advantages of robot-assisted training in rehabilitation therapy, increased funding for medical robot research, and IPOs issued by medical robot companies. However, safety concerns over robotic surgery devices are expected to limit the market growth to some extent. Recent studies have found a number of technical difficulties and complications experienced while performing procedures using robotic systems. According to the FDA, from 2000 to 2013, surgical robots have been linked to over 144 deaths, over 1,391 injuries, and 8,061 device malfunctions.
Read More
10 Aug 2018
Deep Learning-Based System Detects Lesions in Knee MR Images
Researchers from the department of radiology at the University of Wisconsin School of Medicine and Public Health have developed a deep learning approach to detect cartilage lesions by evaluating MR images of the knee. The researchers used segmentation and classification convolutional neural networks (CNNs) to develop the fully automated deep learning–based cartilage lesion detection system.
Read More
10 Aug 2018
New AI Software Cuts Radiation Therapy Planning Time
Researchers from the University of Toronto have developed automation software that will cut down the time for developing radiation therapy plans — individualized maps that help doctors determine where to blast tumors — from days to mere hours.
Read More
10 Aug 2018
RSNA Announces AI and Machine-Learning Initiatives for 2018
The Radiological Society of North America has planned a diverse roster of machine learning (ML) and artificial intelligence (AI) programming for RSNA 2018 that will focus on the power and potential of AI in radiology and issues associated with implementation.
Read More
10 Aug 2018
Global Market for Machine Learning to Surpass USD 2 Billion by 2023
The global market for machine learning in medical imaging is expected to record a robust growth and surpass USD 2 billion by 2023, driven by benefits such as enhanced productivity, increased diagnostic accuracy, more personalized treatment planning and improved clinical outcomes. However, the market is still in the innovator and early adopter phase, and will need to overcome several barriers before AI becomes mainstream in medical imaging. These are the latest findings of Signify Research, an independent supplier of market intelligence and consultancy to the global healthcare technology industry.
Read More
09 Aug 2018
Stago Connect.One Network Allows Remote Monitoring of Analyzers
Diagnostica Stago, an in-vitro diagnostics company focusing on thrombosis and hemostasis, has launched the secure Connect.One network architecture, which allows laboratories to benefit from remote monitoring of their automated analyzers.
Read More
31 Jul 2018
DIAsource Immunoassays Enters Agreement with ZenTech for RIA Products
DIAsource Immunoassays, a BioVendor group company, has entered into a strategic agreement with ZenTech under which ZenTech will transfer its portfolio of radioimmunoassays (RIA) products to DIAsource, securing their continued production and sales.
Read More
31 Jul 2018
Report Shows Micro-Machined Ultrasound Transducers Market Growing
Micro-machined ultrasonic transducers (MUTs), in the form of PMUTs (Piezoelectric micro-machined ultrasonic transducers) and CMUTs (capacitive micro-machined ultrasonic transducers), are finally coming to market. New applications, along with improved manufacturing capabilities and advanced technological readiness, are driving the impressive growth of MUTs.
Read More
31 Jul 2018
Machine-Learning Algorithm Analyzes Images to Identify Schizophrenia Patients
A team of researchers from the University of Alberta has developed a machine-learning algorithm to examine functional magnetic resonance imaging (fMRI) images for identifying patients suffering from schizophrenia and ascertaining if they would respond to treatment. In a study, the algorithm examined MRI images of both newly diagnosed, previously untreated schizophrenia patients and healthy subjects and successfully identified patients with schizophrenia at 78% accuracy. It also predicted whether or not a patient would respond positively to a specific antipsychotic treatment named risperidone with 82% accuracy.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions